Employees Retirement System of Texas Sells 216,622 Shares of Icon Plc $ICLR

Employees Retirement System of Texas decreased its holdings in Icon Plc (NASDAQ:ICLR) by 94.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,901 shares of the medical research company’s stock after selling 216,622 shares during the period. Employees Retirement System of Texas’ holdings in Icon were worth $2,169,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Toth Financial Advisory Corp bought a new position in shares of Icon in the 4th quarter valued at $27,000. Ameriflex Group Inc. bought a new position in shares of Icon in the 3rd quarter valued at $33,000. Johnson Financial Group Inc. bought a new position in shares of Icon in the 3rd quarter valued at $71,000. Quadrant Capital Group LLC bought a new position in shares of Icon in the 3rd quarter valued at $78,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

Icon Stock Performance

Shares of Icon stock opened at $118.45 on Thursday. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The firm has a market capitalization of $9.57 billion, a price-to-earnings ratio of 16.03, a PEG ratio of 2.97 and a beta of 1.23. The business has a 50-day simple moving average of $111.55 and a 200 day simple moving average of $141.66. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06.

Icon (NASDAQ:ICLR) last issued its earnings results on Wednesday, May 27th. The medical research company reported $2.52 EPS for the quarter, missing analysts’ consensus estimates of $3.14 by ($0.62). Icon had a net margin of 7.40% and a return on equity of 10.58%. The firm had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period in the previous year, the firm earned $3.43 earnings per share. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, research analysts anticipate that Icon Plc will post 11.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ICLR has been the topic of several recent analyst reports. Jefferies Financial Group set a $135.00 price target on Icon and gave the company a “buy” rating in a research note on Monday, February 23rd. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Citigroup reduced their price objective on Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. BMO Capital Markets upgraded Icon from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $100.00 to $130.00 in a research report on Thursday, March 26th. Finally, Weiss Ratings lowered Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $147.67.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.